Apolipoprotein L (APOL1) Antibody Pair

Documentos del producto

Especificaciones del producto

Antibody Pairs

Apolipoprotein L (APOL1)

Capture Host: Rabbit
Detection Host: Rabbit

Human

Concentration Capture Antibody: 0.5 mg/ml  
Concentration Biotin-Conjugated Detection Antibody: 0.2 mg/ml
Reconstitute the standard with Standard Diluent. 
The volume, and therefore standard concentration, should be determined by the end user.

Sandwich

2.5 ng/ml - 160 ng/ml

Dilute the Capture Antibody 125-fold with Coating Buffer.  
Dilute the Biotin-Conjugated Detection Antibody 200-fold with Detection Antibody Diluent. 
Optimal dilutions/concentrations should be determined by the end user.

Capture Clonality: Polyclonal
Detection Clonality: Polyclonal

Biotin

5 × 96 tests

10 × 96 tests

Standard form: Lyophilized
Capture Ab: Liquid
Detection Ab: Liquid

ELISA

The Capture and Detection Antibody both contain 0.05% Proclin-300, 50% glycerol.

Please enquire.

Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

No

APOL1, APO-L, APOL, APOL-I, FSGS4, apolipoprotein L1, APO L1

Antibody pair for APOL1

RUO

THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Background

Apolipoprotein L1 (APOL1) is a member of the Apolipoprotein L gene family and plays a critical role in lipid transport and innate immunity. APOL1 is primarily expressed in the liver, kidney, and vascular endothelium and is known for its ability to bind high-density lipoprotein (HDL) particles, contributing to lipid transport and cholesterol metabolism. A particularly vital function of APOL1 lies in its role in innate immunity, as it helps protect against trypanosome infections. APOL1 can lyse trypanosomes such as Trypanosoma brucei, which cause African sleeping sickness, by disrupting their cellular membranes. Genetic variations, specifically the G1 and G2 risk alleles, have been associated with increased susceptibility to kidney diseases, such as focal segmental glomerulosclerosis (FSGS) and HIV-associated nephropathy (HIVAN), particularly in people of African descent. These alleles enhance APOL1-mediated trypanosome resistance but lead to cytotoxic effects in kidney cells under specific stress conditions. APOL1’s dual role as both a defender against pathogens and a contributor to renal disease makes it a subject of intensive research. Targeting APOL1 signaling pathways may provide therapeutic options for managing kidney diseases and understanding its broader impact on lipid metabolism and immune responses.